• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Sybase

Sybase

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Syros to Present on SY -1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference

    Syros to Present on SY -1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference

  2. Syros Announces FDA Acceptance of IND to Advance SY -1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

    Syros Announces FDA Acceptance of IND to Advance SY -1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

  3. Syros Announces $35 Million Private Placement

    Syros Announces $35 Million Private Placement

  4. TmaxSoft Drives Global Expansion with Nine Key Strategic Appointments in APAC and EMEA

    TmaxSoft Drives Global Expansion with Nine Key Strategic Appointments in APAC and EMEA

  5. Don't Pick BlackBerry

    Its slower cash burn is encouraging, but we remain concerned about end-market demand.

  6. Ask the IRA Gurus

    IRA experts weigh in on a tricky situation a client has with the IRS.

1

©2017 Morningstar Advisor. All right reserved.